ARAV
Price:
$0.0401
Market Cap:
$2.95M
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong K...[Read more]
Industry
Biotechnology
IPO Date
2014-03-21
Stock Exchange
NASDAQ
Ticker
ARAV
According to Aravive, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.05. This represents a change of -124.59% compared to the average of 0.21 of the last 4 quarters.
The mean historical PE Ratio of Aravive, Inc. over the last ten years is -6.94. The current -0.05 PE Ratio has changed -23.98% with respect to the historical average. Over the past ten years (40 quarters), ARAV's PE Ratio was at its highest in in the June 2023 quarter at 1.74. The PE Ratio was at its lowest in in the June 2014 quarter at -19.72.
Average
-6.94
Median
-3.48
Minimum
-39.46
Maximum
-0.33
Discovering the peaks and valleys of Aravive, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 2.27%
Maximum Annual PE Ratio = -0.33
Minimum Annual Increase = -81.28%
Minimum Annual PE Ratio = -39.46
Year | PE Ratio | Change |
---|---|---|
2022 | -0.59 | -48.52% |
2021 | -1.15 | -55.69% |
2020 | -2.60 | -66.75% |
2019 | -7.82 | 2.27% |
2018 | -0.33 | -63.74% |
2017 | -0.91 | -80.95% |
2016 | -4.79 | 9.62% |
2015 | -4.37 | -40.88% |
2014 | -7.39 | -81.28% |
2013 | -39.46 | 1.87% |
The current PE Ratio of Aravive, Inc. (ARAV) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.45
5-year avg
-2.50
10-year avg
-6.94
Aravive, Inc.’s PE Ratio is less than Magenta Therapeutics, Inc. (-0.04), greater than ASLAN Pharmaceuticals Limited (-0.32), less than AVROBIO, Inc. (2.07), greater than Aeglea BioTherapeutics, Inc. (-0.19), greater than Autolus Therapeutics plc (-4.55),
Company | PE Ratio | Market cap |
---|---|---|
-0.04 | $42.44M | |
-0.32 | $1.70M | |
2.07 | $5.24M | |
-0.19 | $48.63M | |
-4.55 | $1.07B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aravive, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Aravive, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Aravive, Inc.'s PE Ratio?
How is the PE Ratio calculated for Aravive, Inc. (ARAV)?
What is the highest PE Ratio for Aravive, Inc. (ARAV)?
What is the 3-year average PE Ratio for Aravive, Inc. (ARAV)?
What is the 5-year average PE Ratio for Aravive, Inc. (ARAV)?
How does the current PE Ratio for Aravive, Inc. (ARAV) compare to its historical average?